Can Pregabalin and Vyvanse Be Taken Together?
Yes, pregabalin and Vyvanse (lisdexamfetamine) can be taken together—there are no documented contraindications or dangerous drug interactions between these medications, and this combination is commonly used in clinical practice for patients with ADHD requiring pain management.
Key Safety Considerations
No Direct Drug Interactions
- The available guidelines and literature do not identify pregabalin as a contraindication to stimulant use 1.
- MAO inhibitors are the primary pharmacological contraindication to stimulants, not gabapentinoids like pregabalin 1.
- Pregabalin works through calcium channel modulation while lisdexamfetamine enhances dopamine and norepinephrine activity—these are distinct mechanisms without overlapping toxicity 2.
Cardiovascular Monitoring Required
- Obtain a detailed cardiac history before initiating Vyvanse, including specific cardiac symptoms and family history of sudden death, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, and long QT syndrome 3.
- Monitor heart rate and blood pressure regularly, as stimulants increase HR by 1-2 beats per minute and BP by 1-4 mm Hg on average 3.
- A subset of patients (5-15%) may experience more substantial increases in HR and BP 3.
Dosing Approach
Vyvanse (Lisdexamfetamine)
- Start at 20-30 mg orally once in the morning 4, 3.
- Increase by 10 mg weekly to a maximum of 70 mg daily 4, 3.
Pregabalin
- Follow standard dosing for the specific pain indication being treated.
- No dose adjustments are required based on concurrent Vyvanse use.
Side Effects to Monitor with This Combination
Common Side Effects
- Decreased appetite is common with Vyvanse and may be compounded by any gastrointestinal effects from pregabalin 3.
- Insomnia can occur with stimulants, while pregabalin may cause sedation—these effects may partially offset each other 3.
- Dizziness and somnolence from pregabalin may be present, particularly during dose titration.
Cardiovascular Changes
- Monitor for increased heart rate and blood pressure from Vyvanse 3.
- This is particularly important as pregabalin does not provide cardiovascular protection.
Mood and Behavioral Monitoring
- Watch for mood destabilization, especially in patients with a family history of bipolar disorder 3.
- Monitor for agitation, irritability, hostility, impulsivity, restlessness, or mania, particularly in the first 24-48 hours after initiation or dose changes 3.
Clinical Pitfalls to Avoid
Do Not Confuse with True Contraindications
- Psychosis is a true contraindication to stimulants 1.
- Glaucoma requires caution with sympathomimetics including stimulants 1.
- Concurrent MAO inhibitor use is an absolute contraindication due to risk of severe hypertension and cerebrovascular accident 1.
- Pregabalin does not fall into any of these categories.
Growth Monitoring in Younger Patients
- Both medications can affect growth velocity if used in children or adolescents 3.
- Stimulants may decrease predicted adult height by 1-2 cm, with effects diminishing by the third year 3.
Substance Use Considerations
- Lisdexamfetamine is a prodrug with lower abuse potential compared to immediate-release amphetamines 5, 6, 7.
- It has been successfully used even in patients with stimulant use disorder 6.
- Pregabalin itself has some abuse potential, so monitor for misuse of either medication.
Discontinuation
- Vyvanse can be discontinued without specific tapering requirements 3.
- Pregabalin typically requires gradual tapering to avoid withdrawal symptoms.